Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir + 2 NRTIs in Treatment-Naïve HIV-2
NCT03224338Phase 2Completed
- Sponsor
- Blueclinical
- Start
- Apr 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolutegravir in human immunodeficiency virus type 2 infection (HIV-2), sponsored by Blueclinical. Started Apr 2017; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 2 infection (HIV-2)
Beyond the preview
Go deeper on NCT03224338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224338.